中文摘要：

Liver cancer, a large proportion of which is hepatocellularcarcinoma （HCC）, is diagnosed in more than700000 people each year worldwide. Liver canceris particularly prevalent in Asia, Sub-Saharan Africaand the South Pacific, where hepatitis B and hepatitisC infection rates are very high. However, due toresistance to chemotherapy, patients with intermediateand advanced-stage disease cannot benefit from thistreatment. Clusterin, which is overexpressed in manydifferent cancers, is a stress-induced cytoprotectiveprotein that confers treatment resistance. Custirsen（OGX-011） is a novel 2＇-methoxyethyl modified phosphorothioateantisense oligonucleotide that targetssecretory clusterin protein expression and is currentlyin clinical trials for patients with different cancers. Inrecent years, a number of different clinical trials havebeen performed, and two phase Ⅲ clinical trials ofcustirsen evaluating combinations with chemotherapyin patients with metastatic castration-resistant prostatecancer and metastatic non-small cell lung cancer arecurrently in progress. The aims of this review are tosummarize the current state of research on clusterin,predict future research directions and analyze thepotential of the clinical application of custirsen in HCC.